PHAT News and Press, Phathom Pharmaceuticals Inc. From 01/16/20

MENLO PARK, Calif. , Jan. 16, 2020 /PRNewswire/ -- Frazier Healthcare Partners announced today the closing of Frazier Life Sciences X, L.P., exceeding its target and closing on more than $617 million in capital commitments in an oversubscribed fundraise. Investing in life sciences ...

Martin Gilligan joins from Celgene Corporation where he led marketing, market access and business development for the Inflammation & Immunology Franchise Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commerci...

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the initiation of PHALCON-HP. In this pivotal Phase 3 clinical trial, clinicians will evaluat...